1.06BMarket Cap-8315P/E (TTM)
1.590High1.520Low4.40MVolume1.550Open1.550Pre Close6.87MTurnover1.71%Turnover RatioLossP/E (Static)672.80MShares1.74552wk High0.76P/B405.84MFloat Cap0.85252wk Low--Dividend TTM256.86MShs Float19.200Historical High--Div YieldTTM4.52%Amplitude0.210Historical Low1.562Avg Price1Lot Size
Opko Health Stock Forum
MT Newswires· 1 min ago
OPKO Health (OPK) subsidiary ModeX Therapeutics said Monday it has been awarded an additional $35 million in funding under a contract with the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority to develop Covid-19 and flu vaccines.
NextPlat: Four-Year Extension of OPKO Healthcare E-Commerce Program in China
Entera Bio and OPKO Health Provide Update on Pk/Pd Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
Conference call begins at 4:30 p.m. Eastern time today
MIAMI (August 7, 2024) – OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2024.
Highlights from the second quarter and recent weeks include the following:
●
Enrollment underway in the MDX2001 Phase 1 trial for the treatment of solid...
No comment yet